Pieter E Postmus
Overview
Explore the profile of Pieter E Postmus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
163
Citations
5426
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Van Doorn-Wink K, Postmus P, De Ruysscher D, Damhuis R
Radiother Oncol
. 2024 Dec;
203():110661.
PMID: 39647529
Background And Purpose: The 90-day mortality following lung cancer treatment is a common performance indicator. The aim of this study was to investigate 90-day mortality following (chemo)radiotherapy for stage I-III...
2.
Hoeijmakers F, Schreurs W, Comans E, Belderbos J, Postmus P, Tollenaar R, et al.
J Thorac Oncol
. 2023 Apr;
17(11):1250-1254.
PMID: 37014165
No abstract available.
3.
van de Beek I, Glykofridis I, Tanck M, Luijten M, Starink T, Balk J, et al.
J Hum Genet
. 2023 Jan;
68(4):273-279.
PMID: 36599954
Previously, we reported a series of families presenting with trichodiscomas, inherited in an autosomal dominant pattern. The phenotype was named familial multiple discoid fibromas (FMDF). The genetic cause of FMDF...
4.
Huyuk M, Fiocco M, Postmus P, Cohen D, von der Thusen J
Histopathology
. 2022 Oct;
82(5):650-663.
PMID: 36282087
Lymph node micrometastases could be one of the reasons for the high recurrence rate after complete surgical resection in stage I-IIIA non-small cell lung cancer (NSCLC). The standard evaluation of...
5.
Sriram J, van de Beek I, Johannesma P, van Werkum M, van der Wel T, Wessels E, et al.
BMC Pulm Med
. 2022 Aug;
22(1):325.
PMID: 36028846
Background: Birt-Hogg-Dubé syndrome (BHD) is an inherited disease caused by pathogenic variants in the FLCN gene. One of the characteristics is the increased risk for spontaneous pneumothorax, likely due to ...
6.
Hoppe B, Stoel B, Postmus P
Am J Respir Crit Care Med
. 2022 Apr;
205(12):1474-1475.
PMID: 35452378
No abstract available.
7.
Hondelink L, Jebbink M, von der Thusen J, Cohen D, Dubbink H, Paats M, et al.
JTO Clin Res Rep
. 2021 Dec;
2(12):100252.
PMID: 34849493
Introduction: With the approval of first-line osimertinib treatment in stage IV EGFR-mutated NSCLC, detection of resistance mechanisms will become increasingly important-and complex. Clear guidelines for analyses of these resistance mechanisms...
8.
Hondelink L, Huyuk M, Postmus P, Smit V, Blom S, von der Thusen J, et al.
Histopathology
. 2021 Nov;
80(4):635-647.
PMID: 34786761
Aims: Immunohistochemical programmed death-ligand 1 (PD-L1) staining to predict responsiveness to immunotherapy in patients with advanced non-small cell lung cancer (NSCLC) has several drawbacks: a robust gold standard is lacking,...
9.
Dai L, Li Y, Liang Y, Zhao J, Chen G, Yin J, et al.
J Thorac Dis
. 2021 May;
13(4):2437-2446.
PMID: 34012591
Background: Lung cancer is one kind of malignant tumor with a high risk for morbidity and mortality compared to other solid organ malignancies. Brain metastases occur in 30-55% of non-small...
10.
Morgensztern D, Cobo Dols M, Aix S, Postmus P, Bennouna J, Fischer J, et al.
Front Oncol
. 2021 Mar;
10:569715.
PMID: 33643895
The standard therapy for advanced stage non-small cell lung cancer (NSCLC) with no actionable gene alterations is a platinum-based chemotherapy doublet and immune checkpoint blocker (ICB), either concurrently or sequentially,...